Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) For The Treatment Of Patients With Relapsed Multiple Myeloma Confirms Very Promising Results In a Phase I/II StudySamantha Pozzi, Stefano Sacchi, Attilio Guarini et al.|Blood|2013Cited by 4
A Phase I/II Study of Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) for the Treatment of Patients with Relapsed Multiple MyelomaStefano Sacchi, Fortunato Morabito, Samantha Pozzi et al.|Blood|2012Cited by 2